<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510599</url>
  </required_header>
  <id_info>
    <org_study_id>CE01-205</org_study_id>
    <nct_id>NCT02510599</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis</brief_title>
  <official_title>An Open Label, Proof of Principle Study to Evaluate the Efficacy and Safety of Solithromycin for the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cempra Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cempra Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of solithromycin on hepatic histology
      and biomarkers in patients with nonalcoholic steatohepatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be administered solithromycin for 13 weeks with regular safety visits and liver
      biopsies at baseline and after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">January 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate effects on hepatic histology in patients with NASH</measure>
    <time_frame>13 weeks</time_frame>
    <description>Using the Nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Steatosis on liver biopsy</measure>
    <time_frame>13 weeks</time_frame>
    <description>Graded from 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hepatocellular ballooning score on liver biopsy</measure>
    <time_frame>13 weeks</time_frame>
    <description>Graded from 0 to 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammation on liver biopsy</measure>
    <time_frame>13 weeks</time_frame>
    <description>Graded from 0 to 3</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Solithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solithromycin</intervention_name>
    <arm_group_label>Solithromycin</arm_group_label>
    <other_name>CEM-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic evidence of NASH based on liver biopsy obtained within 180 days

          -  NAS&gt; or = 5

          -  Able to swallow capsules intact

        Exclusion Criteria:

          -  Symptoms of acute liver disease

          -  Cirrhosis on liver biopsy

          -  Positive HIV or Hepatitis tests

          -  Primary Biliary Cirrhosis

          -  Poorly controlled diabetes with HgA1C &gt;8.5%

          -  ALT &gt;4-fold upper limit of normal

          -  QTcF &gt;450 msec

          -  CrCl &lt;40 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Dobbins, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cempra Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Western University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <disposition_first_submitted>March 17, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 17, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 20, 2017</disposition_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <keyword>Liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

